Submit to Cancers Review for Cancers Propose a Special Issue

Journal Browser

► Journal Browser

Cancer Theranostics

Special Issue Editors
Special Issue Information
Published Papers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (31 January 2022) | Viewed by 8620

Share This Special Issue

Special Issue Editors

Prof. Dr. Markus Luster

E-Mail Website
Guest Editor

Head of Nuclear Medicine Department, University Hospital Marburg, Philipps University Marburg, Marburg, Germany
Interests: Cancer Theragnostics Imaging and Internal Radiotherapy; Prostate Cancer; Adenocarcinoma; Neuroendocrine Tumors; Pancreatic carcinomas

Prof. Dr. Behrooz H. Yousefi

E-Mail Website
Guest Editor

Head of Radiopharmacy, Nuclear Medicine Department, University Hospital Marburg, Philipps University Marburg, 35037 Marburg, Germany
Interests: radiopharmacy; cancer theragnostics imaging and internal radiotherapy; tracer development; glutamate carboxypeptidase II; fibroblast activation protein; neuroendocrine tumors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The word Thera(g)nostics is derived from therapy and diagnostics and refers to the strategy of utilizing the modern diagnostic test in combination with a personalized therapy, i.e., radiotheranostics with radioactively labeled drugs. Cancer radiotheranostics is a cancer treatment strategy that combines therapeutics and diagnostics, aiming for early diagnosis, accurate molecular imaging, and individual patient precise treatment at the right timing and proper dose, followed by real-time monitoring of treatment efficacy.

This Special Issue encourages scientists to bring their expert opinions and research on the state-of-the-art of cancer theragnostics from a variety of genomic, proteomic, and metabolomic biomarkers, applying molecular imaging techniques for in vivo measurement of cancer hallmarks, image-guided cancer interventions, and targeted radioligand or nanoparticle therapies with, e.g., alpha or beta emitters such as radium 223 (Ra-223), lutetium 177 (Lu-177) or actinium 225 (Ac-225) for imaging and therapy of a particular disease.

Furthermore, the challenges of clinical translation of cancer theranostic approaches, multimodality approach, and articles analyzing new insights into elucidating the role of radiotherapy in the management of cancers are invited.

Prof. Dr. Markus Luster
Prof. Dr. Behrooz H. Yousefi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (3 papers)

Download All Papers

Research

17 pages, 1919 KiB

Open AccessArticle

Copper-64-Labeled 1C1m-Fc, a New Tool for TEM-1 PET Imaging and Prediction of Lutetium-177-Labeled 1C1m-Fc Therapy Efficacy and Safety

by Judith Anna Delage, Silvano Gnesin, John O. Prior, Jacques Barbet, Patricia Le Saëc, Séverine Marionneau-Lambot, Sébastien Gouard, Michel Chérel, Mickael Bourgeois, Niklaus Schaefer, David Viertl, Julie Katrin Fierle, Steven Mark Dunn and Alain Faivre-Chauvet

Cancers 2021, 13(23), 5936; https://doi.org/10.3390/cancers13235936 - 25 Nov 2021

Cited by 2 | Viewed by 1965

Abstract

1C1m-Fc, a promising anti-TEM-1 DOTA conjugate, was labeled with ⁶⁴Cu to target cancer cells for PET imaging and predicting the efficacy and safety of a previously studied [¹⁷⁷Lu]Lu-1C1m-Fc companion therapy. DOTA-conjugated 1C1m-Fc was characterized by mass spectrometry, thin layer chromatography and immunoreactivity assessment. PET/CT and biodistribution studies were performed in human neuroblastoma xenografted mice. Absorbed doses were assessed from biodistribution results and extrapolated to ¹⁷⁷Lu based on the [⁶⁴Cu]Cu-1C1m-Fc data. The immunoreactivity was ≥ 70% after 48 h of incubation in serum, and the specificity of [⁶⁴Cu]Cu-1C1m-Fc for the target was validated. High-resolution PET/CT images were obtained, with the best tumor-to-organ ratios reached at 24 or 48 h and correlated with results of the biodistribution study. Healthy organs receiving the highest doses were the liver, the kidneys and the uterus. [⁶⁴Cu]Cu-1C1m-Fc could be of interest to give an indication of ¹⁷⁷Lu dosimetry for parenchymal organs. In the uterus and the tumor, characterized by specific TEM-1 expression, the ¹⁷⁷Lu-extrapolated absorbed doses are overestimated because of the lack of later measurement time points. Nevertheless, 1C1m-Fc radiolabeled with ⁶⁴Cu for imaging would appear as an interesting radionuclide companion for therapeutic application with [¹⁷⁷Lu]Lu-1C1m-Fc. Full article

(This article belongs to the Special Issue Cancer Theranostics)

► Show Figures

Figure 1

23 pages, 3667 KiB

Open AccessArticle

Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer—A New Diagnostic and Therapeutic Target?

by Sabine Wächter, Pietro Di Fazio, Elisabeth Maurer, Jerena Manoharan, Corinna Keber, Andreas Pfestroff, Damiano Librizzi, Detlef K. Bartsch, Markus Luster and Friederike Eilsberger

Cancers 2021, 13(22), 5688; https://doi.org/10.3390/cancers13225688 - 14 Nov 2021

Cited by 10 | Viewed by 2219

Abstract

Several studies have demonstrated an expression of the prostate-specific membrane antigen (PSMA) in the cancer-related neovasculature of thyroid malignancies. Due to the poor prognosis and limited therapeutic options for patients with anaplastic (ATC) and poorly differentiated (PDTC) thyroid carcinoma, the aim of our study was to investigate the theranostic approach of PSMA expression in these patients. The PSMA uptake on Gallium-68 (⁶⁸Ga)-PSMA-positron emission tomography/computed tomography (PET/CT) and glucose uptake on F-18-Fluordeoxyglucose (¹⁸F-FDG)-PET/CTs were analysed in two ATC and six PDTC patients. The PSMA expression in corresponding patients’ tissue samples was detected by immunohistochemistry. In addition, various tissue sections from 22 ATC and six PDTC patients were examined concerning PSMA expression. ⁶⁸Ga-PSMA-PET/CT showed heterogeneous PSMA expression among patients and lesions. Six of the eight analyzed patients (two ATC, four PDTC) showed increased glucose metabolism without increased PSMA uptake after PET/CT. In one patient (PDTC), ¹⁸F-FDG-PET/CT tracer uptake was positive and ⁶⁸Ga-PSMA-PET/CT showed heterogeneous results. Another patient (PDTC) evidenced only PSMA-positive lesions and received two cycles of Lutetium-177 (¹⁷⁷Lu)-PSMA therapy, which kept his disease stable for seven months. There was a correlation between immunohistochemical PSMA expression and uptake on ⁶⁸Ga-PMSA-PET/CT in three of the examined patients. Twenty-seven of the analyzed 39 ATC and 13 of the analyzed 22 PDTC tissue sections showed a strong PSMA expression. Considering the rarity of PDTC and ATC, which is the reason for the small patient population we studied, the findings of this study confirm the high diagnostic sensitivity and superiority of ¹⁸F-FDG-PET/CT in comparison to ⁶⁸Ga-PSMA-PET/CT in the diagnosis of ATC and PDTC. However, it can be suggested that ⁶⁸Ga-PMSA-PET/CT can be considered as a beneficial adjunct to the well-established ¹⁸F-FDG-PET/CT for a few individual selected patients with ATC and PDTC to detect lesions not discovered by ¹⁸F-FDG-PET/CT and to determine patients’ eligibility for a radioligand therapy. Radiolabelled PSMA-ligands may, in the future, represent a theranostic approach with only minor side effects for a few individual selected patients with ATC and PDTC who need alternative treatment options in case of progression when established therapies are no longer effective. However, due to the small sample size of our collective, larger studies are needed to allow for a final evaluation on the significance of PSMA-targeted diagnostic and therapy for ATC and PDTC. Full article

(This article belongs to the Special Issue Cancer Theranostics)

► Show Figures

Figure 1

13 pages, 793 KiB

Open AccessArticle

The Importance of Clinical Examination under General Anesthesia: Improving Parametrial Assessment in Cervical Cancer Patients

by Paulina Sodeikat, Massimiliano Lia, Mireille Martin, Lars-Christian Horn, Michael Höckel, Bahriye Aktas and Benjamin Wolf

Cancers 2021, 13(12), 2961; https://doi.org/10.3390/cancers13122961 - 13 Jun 2021

Cited by 5 | Viewed by 2703

Abstract

Background: Parametrial tumor involvement is an important prognostic factor in cervical cancer and is used to guide management. Here, we investigate the diagnostic value of clinical examination under general anesthesia (EUA) and magnetic resonance imaging (MRI) in determining parametrial tumor spread. Methods: Post-operative pathological findings of 400 patients with primary cervical cancer were compared to the respective MRI data and the results from EUA. The gynecological oncologist had access to the MR images during clinical assessment (augmented EUA, aEUA). Results: Pathologically proven parametrial tumor invasion was present in 165 (41%) patients. aEUA exhibited a higher accuracy than MRI alone (83% vs. 76%; McNemar’s odds ratio [OR] = 2.0, 95%CI 1.25–3.27, p = 0.003). Although accuracy was not affected by tumor size in aEUA, MRI was associated with a lower accuracy in tumors ≥2.5 cm (OR for a correct diagnosis compared to smaller tumors 0.22, p < 0.001). There was also a decrease in specificity when evaluating parametrial invasion by MRI in tumors ≥2.5 cm in diameter (p < 0.0001) compared to smaller tumors (< 2.5 cm). Body mass index had no influence on performance of either method. Conclusions: aEUA has the potential to increase the diagnostic accuracy of MRI in determining parametrial tumor involvement in cervical cancer patients. Full article

(This article belongs to the Special Issue Cancer Theranostics)

► Show Figures

Figure 1

Journal Menu

Journal Browser

Cancer Theranostics

Share This Special Issue

Special Issue Editors

Special Issue Information

Published Papers (3 papers)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI